Precipitation of fluticasone propionate microparticles using supercritical antisolvent

Daru

Volumn 17, Issue 1, 2009, Pages 6-12

  Vatanara, A ^a   Rouholamini, Najafabadi A ^a,b   Gilani, K ^a   Asgharian, R ^a   Darabi, M ^a   Rafiee Tehrani, M ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b PASTEUR INSTITUTE OF IRAN   (Iran)

Author keywords

Fluticasone; Microparticles; Precipitation; Supercritical fluids

Indexed keywords

CARBON DIOXIDE; FLUTICASONE PROPIONATE;

ARTICLE; ATMOSPHERIC PRESSURE; DISSOLUTION; DRUG DESIGN; DRUG FORMULATION; DRUG MANUFACTURE; DRUG SOLUBILITY; ENVIRONMENTAL TEMPERATURE; PARTICLE SIZE; PHYSICAL CHEMISTRY; PRECIPITATION; SUPERCRITICAL FLUID; TEMPERATURE DEPENDENCE; THERMAL ANALYSIS;

EID: 62649122876     PISSN: 15608115     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Rehman M, Shekunov BY, York P, Lechuga-Ballesteros D, Miller DP, Tan T, Colthorpe P. Optimisation of powders for pulmonary delivery using supercritical fluid technology. Eur. J Pharm Sci 2004; 22,1-17.
2. Pasquali I, Bettini R, Giordano F. Solid-state chemistry and particle engineering with supercritical fluids in pharmaceutics, Eur J Pharm Sci 2006; 27, 299-310.
3. Velaga SP, Ghaderi R, Carlfors J. Preparation and characterisation of hydrocortisone particles using a supercritical fluids extraction process, Int J Pharm 2002; 231, 155-166.
4. Subramaniam B, Rajewski R, Snavely K. Pharmaceutical processing with supercritical carbon dioxide, J Pharm Sci 1997; 86, 885-890.
5. Krober H, Teipel U. Materials processing with supercritical antisolvent precipitation: process parameters and morphology of tartaric acid, J Supercritical Fluids 2002; 22: 229-235.
6. Thiering R, Dehghani F, Foster NR, Current issues relating to anti-solvent micronisation techniques and their extension to industrial scales, J Supercritical Fluids 2001; 21, 159-177.
7. Jung J, Perrut M. Particle design using supercritical fluids: Literature and patent survey, J Supercritical Fluids 2001; 20, 179-219.
8. Laugher L, Noctor TG, Barrow A, Oxford JM, Phillips T. An improved method for the determination of fluticasone propionate in human plasma, J Pharm Biomed Anal 1999; 21, 749-758.
9. Vatanara A, Rouholamini Najafabadi A, Khajeh M, Yamini Y. Solubility of some inhaled glucocorticoids in supercritical carbon dioxide, J Supercritical Fluids 2005; 33, 21-25.
10. Steckel H, Thies J, Mul̈ler W. Micronizing of steroids for pulmonary delivery by supercritical carbon dioxide. Int J Pharm. 1997; 152, 99-110.
11. Steckel H. Muller BW. Metered-dose inhaler formulation of fluticasone-17-propionate micronized with supercritical carbon dioxide using the alternative propellant HFA-227. Int J Pharm 1998; 173, 25-33.
12. Rouholamini Najafabadi A, Vatanara A, Gilani K, Rafiee Tehrani M. Formation of salbutamol sulphate microparticles using solution enhanced dispersion by supercritical carbon dioxide Daru 2005; 13 (1):1-6.
13. British Pharmacopoeia, Her Majesty's Stationery Office, London, 2005.
14. Reverchon E, Della Porta G, Pallado P. Supercritical antisolvent precipitation of salbutamol microparticles, Powder Technol 2001; 114, 17-22.
15. Hawthorn SB, King JW. Principles and practice of analytical SFE, In: Cavde M, Thiebaut D. (Ed) Practical supercritical fluid chromatography and extraction, Harwood Academic Publishers, Australia, 1999; 253-254.
16. Lang Q, Wai CM. Supercritical fluid extraction in herbal and natural product studies - a practical review. Talanta 2001; 53, 771-782.
17. Yeo SD, Lee JC. Crystallization of sulfamethizole using the supercritical and liquid antisolvent processes, J Supercritical Fluids 2003; 30, 315-323.
18. Park HJ, Kim MS, Lee S, Kim JS, Woo JS, Park, JS, Hwang SJ. Recrystallization of fluconazole using the supercritical antisolvent (SAS) process. Int J Pharm 2007; 328, 152-160.
19. Chang CJ, Day CY, Ko CM, Chiu KL. Densities and P-x-y diagrams for carbon dioxide dissolution in methanol, ethanol, and acetone mixtures. Fluid Phase Equilibria 1997; 131, 243-258.
20. Stievano M, Elvassore N. High-pressure density and vapor-liquid equilibrium for the binary systems carbon dioxide-ethanol, carbon dioxide-acetone and carbon dioxide-dichloromethane. J Supercritical Fluids 2005; 33, 7-14.
21. Telko MJ, Hickey AJ. Dry powder inhaler formulation, Respiratory Care. 2005; 50, 1209-1227.
22. Rouholamini Najafabadi A, Gilani K, Barghi M, Rafiee-Tehrani M. The effect of vehicle on physical properties and aerosolisation behaviour of disodium cromoglycate microparticles spray dried alone or with l-leucine. Int J Pharm 2004; 285, 97-108.
23. Yeo SD, Kim MS, Lee JC. Recrystallization of sulfathiazole and chlorpropamide using the supercritical fluid antisolvent process, J Supercritical Fluids 2003; 25,143-154.
24. Zeng XM, Martin GP, Marriott C. Particulate interaction in dry powder formulations for inhalation. 1998; Taylor and Francis, London, 210-249.
25. Young PM, Price R. The influence of humidity on the aerosolisation of micronised and SEDS produced salbutamol sulphate, Eur J Pharm Sci 2004; 22, 235-240.